Drug Database
IN

interferon gamma (Heberon Gamma R / Heberon Gamma)

✓ Approved

Heber Biotec · IFNG · 重组蛋白

什么是 interferon gamma?

interferon gamma 是一种重组蛋白,由Heber Biotec研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Heberon Gamma R, Heberon Gamma
公司Heber Biotec
药物类别重组蛋白
分子靶点IFNG
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

作用机制

分子靶点

interferon gamma 作用于 1 个分子靶点:

IFNGinterferon gamma (IMD69, IFI)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

interferon gamma 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved
Infections and infestationsDisseminated mycobacterium avium complex infectionPhase I

相关研究文献

PubMedVeterinary medicine and science2026-11-19

Early Changes in Serum Protein Electrophoresis and Gamma Globulin during Initial 4 Weeks of Remdesivir Therapy in FIP Cats.

Khalili Kosar K, Cheraghi Hadi H, Saljooghian Isfahani Mohammad Hossein MH

Feline infectious peritonitis (FIP) is a fatal multisystem inflammatory disorder of cats that was historically considered untreatable before the emergence of direct-acting antivirals. The objective of the study was to evaluate early serial changes in serum protein electrophoresis (SPE) patterns in cats treated with remdesivir for FIP, emphasizing gamma-globulin concentrations and percentages. Animals included eighteen client-owned cats diagnosed with FIP based on clinical presentation, standard clinicopathological profiles, and confirmatory RT-PCR. Cats received remdesivir for 4 weeks and were monitored weekly through clinical examinations and laboratory evaluations. Blood samples were collected at baseline (prior to treatment initiation) and weekly for 4 weeks. The SPE analyzed the blood taken every week for the serum protein fractions, such as albumin and the different globulins, namely α1-, α2-, β1-, β2-, and γ-globulins. The albumin to globulin ratio (A/G ratio) was also determined. Gamma globulins were found to be significantly reduced from a median of 3.1 g/dL at week 2 to a median of 2.2 g/dL at the end of week 4 (p < .05) in cats that showed clinical response. Notably, ROC curve analysis identified that a gamma-globulin percentage <23% at week 4 and 18.96% by week 6 (AUC = 0.9105) was strongly associated with complete clinical recovery and sustained relapse-free remission. Serial monitoring of serum protein electrophoresis, particularly longitudinal trends in gamma-globulin percentages and the A/G ratio, provides an objective, practical biomarker strategy to evaluate treatment response and guide the safe timing of antiviral therapy cessation in cats with FIP.

PMID 43052221
阅读全文 →
PubMedNature communications2026-11-19

Tumor-intrinsic PTPN12 suppresses anti-tumor immunity in colorectal cancer by restraining a dual epigenetic and cytoskeletal dsRNA sensing program.

Huo Yachang Y, Tian Yijun Y, Wang Dan D, Ping Yu Y et al.

Innate sensing of endogenous double-stranded RNA and the ensuing interferon response are crucial for the efficacy of immune checkpoint inhibition. Microsatellite stable colorectal cancer characteristically lacks this response, remaining immune-refractory with undefined intrinsic regulators. Here, through an in vivo clustered regularly interspaced short palindromic repeats screen, we identify PTPN12 as a physiological barrier that suppresses double-stranded RNA sensing and interferon response. TRIM28 was identified as a direct PTPN12 substrate here; PTPN12 removes phosphorylation at Y370 to stabilize repressive complexes and silence transposable elements, while concurrently rewiring the adhesive cytoskeleton to disrupt the spatially organization of cytosolic double-stranded RNA required for efficient innate sensing. Pharmacological inducible PTPN12 knockdown inhibits pre-established tumor growth and overcomes immunotherapy resistance in vivo, recapitulating PTPN12 ablation-induced massive double-stranded RNA accumulation. Our findings reveal a role for PTPN12 in coupling epigenetic silencing with cytoskeletal surveillance, suggesting potential strategies to augment anti-tumor immunity and overcome immunotherapy resistance in microsatellite stable colorectal cancer.

PMID 43052240
阅读全文 →
PubMedPulmonology2026-11-19

Nebulized interferon-β1a (SNG001) in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.

Qin Jinlv J, Wang Guizuo G, Han Dong D

This systematic review and meta-analysis aimed to determine the efficacy of nebulised interferon-β1a (SNG001) in patients with Coronavirus disease-2019 (COVID-19). A systematic search was conducted across PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Studies were searched up to November 2025. Randomised controlled trials (RCTs) on treatment of COVID-19 with SNG001, compared with placebo or standard of care, were reviewed. Data were analysed using the RevMan Version 5.1 (The Cochrane Collaboration). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. Four RCTs (enrolling 1055 participants) met the inclusion criteria. The proportion of patients with hospitalisations (data extracted from two RCTs) (RR 0.16, 95% CI 0.03 to 0.88), and serious adverse events (RR 0.65, 95% CI 0.47 to 0.90) were significantly fewer in SNG001 groups. There was no statistically significant difference in all-cause mortality (RR 0.72, 95% CI 0.37 to 1.39), patients non-recovery at day 28 (RR 0.87, 95% CI 0.65 to 1.17), and adverse event (RR 0.97, 95% CI 0.90 to 1.04) between the two groups. Nebulised SNG001 was safe and associated with a reduction in COVID-19-related hospital admission. SNG001 shows a potential benefit for outpatients with COVID-19, but it requires larger clinical trials for future validations, particularly in vaccinated and previously infected populations.

PMID 43053745
阅读全文 →
PubMedCancer immunology, immunotherapy : CII2026-11-19

Tumor-associated antigen-reactive T cells and clinical outcomes in head and neck squamous cell carcinoma treated with pembrolizumab plus chemotherapy.

Sato Ryosuke R, Sakaue Shota S, Ominato Hisataka H, Inoue Takahiro T et al.

Blood-based biomarkers associated with clinical outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab plus chemotherapy remain poorly defined. We investigated 38 patients with HNSCC treated with pembrolizumab plus 5-fluorouracil and platinum (FP). Baseline systemic inflammation and immune status were assessed using routine laboratory parameters. Peripheral blood mononuclear cells were analyzed by flow cytometry to assess exhaustion- and activation-associated markers on CD4⁺ and CD8⁺ T cells, including CD38, Tim-3, PD-1, and ICOS. Tumor-associated antigen (TAA)-reactive immune responses were evaluated by interferon-γ production following stimulation with epidermal growth factor receptor (EGFR)- and c-Met-derived peptides. PD-L1 CPS positivity, elevated neutrophil-to-lymphocyte ratio, and higher frequencies of CD8⁺CD38⁺ T cells were associated with clinical outcomes, with similar trends observed for selected inflammatory and peripheral T-cell activation/exhaustion-associated markers. Tumor-associated antigen-reactive immune responses were detected in a subset of patients and were associated with prolonged progression-free survival, while EGFR peptide reactivity was additionally associated with improved overall survival. In this exploratory study, immune reactivity to TAAs was associated with favorable clinical outcomes in patients receiving pembrolizumab plus FP. Together with systemic inflammation and peripheral T-cell activation/exhaustion markers, these findings support further evaluation of integrated blood-based immune profiling, including TAA-reactive immune responses, as candidate biomarkers in larger prospective cohorts.

PMID 43052553
阅读全文 →
PubMedPediatric research2026-11-19

Kernicteric Gunn rat pups with dystonia exhibit selective loss of parvalbumin expressing neurons in the globus pallidus.

Yang Fu-Chen FC, Stanford John A JA, Shapiro Steven M SM

Kernicterus is a devastating permanent neurological condition resulting from bilirubin neurotoxicity. Damage to globus pallidus (GP) results in severe dystonia. Most GP neurons express gamma-aminobutyric acid (GABA), but which GP neuron subtypes are vulnerable to bilirubin toxicity is unknown. We used the jaundiced Gunn rat model to test the hypothesis that bilirubin selectively damages parvalbumin expressing (PV+) GP neurons. Jaundiced (jj) rat pups and non-jaundiced (Nj) littermates were weight matched. One jj group was injected with sulfadimethoxine 100 mg/kg to produce severe dystonia; jj and Nj-control groups each received saline. Four days later, brains were collected for NeuN and PV immunohistochemical analyses to identify total neurons and PV phenotype neurons in the GP. All jj-sulfa rats exhibited severe dystonia; Nj-controls and jj-controls had no dystonia. The number of PV+ neurons decreased significantly in the jj-sulfa group compared to Nj controls. However, the number of non-PV GP neurons did not differ between the jj-sulfa and Nj controls. Bilirubin neurotoxicity in the GP is cell-type specific. This preliminary study provides novel information regarding neonatal bilirubin toxicity and a potential therapeutic target for treating severe, intractable dystonia resulting from kernicterus. Using the sulfa-treated Gunn rat model of kernicterus, we show that neonatal hyperbilirubinemia results in selective loss of parvalbumin expressing neurons in the globus pallidus. This finding identifies the population of globus pallidus neurons that are lost in kernicterus. Dystonia in kernicterus is believed to result from damage to the globus pallidus. This study identifies a target for cell replacement therapy.

PMID 43052347
阅读全文 →
PubMedBMC gastroenterology2026-11-19

Signal mining and safety profile analysis of prucalopride: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.

Meng Zhongjing Z, Li Wenjing W, Lu Jin J, Zhan Guanjun G

Prucalopride is a highly selective 5-HT4 agonist used for chronic idiopathic constipation and gastroparesis. Although clinical trials suggest a favorable safety profile, real-world data on rare adverse events (AEs) remain scarce. This study mined the FDA Adverse Event Reporting System (FAERS) to detect safety signals warranting clinical attention. FAERS data from December 14, 2018 to September 30, 2025 were collected via OpenVigil 2.1. AEs were categorised using the Medical Dictionary for Regulatory Activities. Signal detection was performed using four specific algorithms: the Proportional Reporting Ratio (PRR), the Reporting Odds Ratio (ROR), the Multi-item Gamma Poisson Shrinker (MGPS), and the Bayesian Confidence Propagation Neural Network (BCPNN). Kappa consistency and sensitivity analyses were performed. We collected 1101 prucalopride-related reports and identified 35 positive adverse drug event (ADE) signals across 10 system organ classes. Gastrointestinal disorders dominated (12 signals, 373 cases), followed by psychiatric disorders (9 signals, 107 cases) and nervous system disorders (5 signals, 181 cases). Frequent reactions included headache, diarrhoea, nausea, dizziness and abdominal pain. Signal intensity varied across algorithms; gastrointestinal bacterial overgrowth emerged as a strong signal in all four. We found 19 ADEs that were not listed in the prescribing information of China, the United States, or Europe; serious unlabeled signals included intestinal obstruction and serotonin syndrome. Notably, depression, suicidal ideation, depressed mood, and nightmares appear only in the United States prescribing information. Prucalopride-related ADEs involve multiple organ systems, predominantly presenting as gastrointestinal disorders, psychiatric disorders and nervous system disorders. Some ADEs not included in the instructions may be serious adverse events, require great attention from clinicians. For patients with underlying comorbidities or those undergoing combination therapy, close monitoring for potential severe adverse events is essential to ensure clinical medication safety.

PMID 43052814
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多interferon gamma